Gilead Sciences Inc.
Company Profile
Business Description
Gilead Sciences Inc. is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines for serious and life-threatening diseases. The company’s core franchise centers on therapies for HIV and viral hepatitis, including hepatitis B and C, where its antiviral portfolio remains widely used in clinical practice. Beyond infectious diseases, Gilead Sciences has expanded meaningfully into oncology, offering cell therapies such as CAR-T treatments for certain blood cancers and antibody-drug conjugates used in breast and bladder cancer care. It also maintains programs in liver diseases, inflammatory conditions, and respiratory disorders, aiming to address areas of high unmet medical need. Headquartered in Foster City, California, and founded in 1987, Gilead Sciences plays a significant role in the healthcare sector by supplying advanced therapeutics to hospitals, clinics, and healthcare systems worldwide, often in collaboration with research institutions and commercial partners.
Profitability & Growth
Profitability
Recent Year-End
Balance Sheet Snapshot
Total Cash (MRQ)
7.94B
Total Debt (MRQ)
17.93B
Current Ratio (MRQ)
1.97
Book Value / Share
15.24